Many critical questions remain about the effectiveness of COVID-19 vaccines in real-world settings. These questions can only be answered in post-introduction vaccine effectiveness studies.This guidance document outlines an approach to leverage existing surveillance systems for Severe Acute Respirato...ry Infection (SARI) to estimate COVID-19 vaccine effectiveness (VE) in preventing SARI associated with laboratory-confirmed SARS-CoV-2 using  existing SARI  surveillance  systems. The  approach  uses  the test-negative  design  to  evaluate  VE;  cases  are  SARI  patients  who  tested  positive  for  SARS-CoV-2,  and controls are SARI patients who tested negative for SARS-CoV-2.
                                                                    more
                                                            
                         
                     
                                                        
                        
                        
                            
                            
                                                                Vaccinator's Manual. MODERNA Vaccine
                                                            
                         
                     
                                                        
                        
                        
                            
                            
                                                                Diese Faktenboxen sollen Ihnen helfen, Nutzen und Schaden einer Schutzimpfung gegen COVID-19 abzuwägen. Die Informationen und Zahlen stellen keine endgültige Bewertung dar. Sie basieren auf den derzeit besten wissenschaftlichen Erkenntnissen.
                                                            
                         
                     
                                                        
                        
                        
                            
                            
                                                                FEY ENFOMASYON POU MOUN K’AP RESEVWA AVEK MOUN K’AP BAY SWEN OTORIZASYON POU ITILIZASYON IJANS (EUA) POU  VAKSIN MODERNA COVID-19 POU ANPECHE CORONAVIRUSDISEASE 2019 
(COVID-19) NAN PERSONN 18 ANE AK PI GRAN
                                                            
                         
                     
                                                        
                        
                        
                            
                            
                                                                Vaccinator's Manual. Pfizer-BioNTech Comirnaty Vaccine
                                                            
                         
                     
                                                        
                        
                        
                            
                            
                                                                Comment The Lancet Volume 397, ISSUE 10269, P72-74, January 09, 2021
Published:December 08, 2020DOI:https://doi.org/10.1016/S0140-6736(20)32623-4
                                                            
                         
                     
                                                        
                        
                        
                            
                            
                                                                MEDBOX Issue Brief no. 7, Dec. 2020
Die Impfung gegen die Ausbreitung des SARS-CoV-2-Virus stellt einen Meilenstein in der Bekämpfung der Pandemie dar. Für den Erfolg der Impfung unabdingbar ist eine gute Kommunikation und Aufklärung der Bevölkerung. Im Folgenden sind einige Informationen zur I...mpfstrategie, Durchführung der Impfung, ethische Überlegungen, sowie Aufklärungsmaterialien in deutscher und englischer Sprache aufgelistet
                                                                    more
                                                            
                         
                     
                                                        
                        
                        
                            
                            
                                                                On the 9 February 2021, Africa CDC convened a special session of the Africa Task Force for COVID-19 to review existing data and evidence and recommend
                                                            
                         
                     
                                                        
                        
                        
                            
                            
                                                                Manufacturers:
    SK Bioscience Co. Ltd. [COVID-19 Vaccine (ChAdOx1-S [recombinant])] 
    Serum Institute of India Pvt. Ltd. [COVISHIELD™, ChAdOx1 nCoV-19 Corona Virus Vaccine (Recombinant)]
Efficacy shown in clinical trials in participants who received the full series of vaccine (2 doses) ir...respective of interval between the doses was 63.1%, based on a median follow-up of 80 days, but tended to be higher when this interval was longer. The data reviewed at this time support the conclusion that the known and potential benefits of ChAdOx1-S/nCoV-19 [recombinant] vaccine outweigh the known and potential risks.
                                                                    more
                                                            
                         
                     
                                                        
                        
                        
                            
                            
                                                                Information about vaccine administration
                                                            
                         
                     
                                                        
                        
                        
                            
                            
                                                                February 2021.
Improving our response to the ongoing COVID-19 pandemic in Africa requires regularly updated information, constant innovation, and considerable support towards research and development (R&D) for priorities that respond to the African realities. Shaping the research agenda and stimula...ting the generation, translation, and dissemination of valuable knowledge is one of the core functions of the African Academy of Sciences (AAS), African Centre for Disease Control (Africa CDC), and WHO-AFRO. We need answers to a list of critical research questions that respond to the current realities on the African continent to guide the COVID-19 outbreak control efforts
                                                                    more
                                                            
                         
                     
                                                        
                        
                        
                            
                            
                                                                Este documento de referência foi preparado pelo Grupo de Trabalho sobre Vacinas contra COVID-19 do Grupo Consultivo Estratégico de Especialistas em Imunização (SAGE) para orientar as discussões do SAGE em sua reunião extraordinária de 8 de fevereiro de 2021, que resultou na publicação do do...cumento da OMS de 10 de fevereiro de 2021 Recomendações provisórias para o uso da vacina AZD1222 [ChAdOx1-S (recombinante)] contra COVID-19 desenvolvida pela Universidade de Oxford e pela AstraZeneca. Os dois documentos estão disponíveis na página sobre COVID-19 do SAGE: https://www.who.int/groups/strategic-advisory-group-of-experts-on-immunization/covid-19-materials. Têm sido usados vetores de adenovírus deficientes na replicação contendo um transgene específico do patógeno como novas vacinas devido à sua capacidade de induzir respostas humorais e celulares fortes.
                                                                    more
                                                            
                         
                     
                                                        
                        
                        
                            
                            
                                                                10 May 2021. Manufactureres:
    SK Bioscience Co. Ltd. [COVID-19 Vaccine (ChAdOx1-S [recombinant])] 
    Serum Institute of India Pvt. Ltd. [COVISHIELD™, ChAdOx1 nCoV-19 Corona Virus Vaccine (Recombinant)]
 The ChAdOx1-S/nCoV-19 [recombinant] vaccine is a replication-deficient adenoviral vecto...r vaccine against coronavirus disease 2019 (COVID-19). The vaccine expresses the SARS-CoV-2 spike protein gene, which instructs the host cells to produce the protein of the S-antigen unique to SARS-CoV-2, allowing the body to generate an immune response and to retain that information in memory immune cells. Efficacy shown in clinical trials in participants who received the full series of vaccine (2 doses) irrespective of interval between the doses was 63.1%, based on a median follow-up of 80 days, but tended to be higher when this interval was longer. The data reviewed at this time support the conclusion that the known and potential benefits of ChAdOx1-S/nCoV-19 [recombinant] vaccine outweigh the known and potential risks.
                                                                    more
                                                            
                         
                     
                                                        
                        
                        
                            
                            
                                                                REG 174 INFORMATION FOR UK HEALTHCARE PROFESSIONALS